Moderna, Inc. (MRNA)

↓ Download CSV

CIK 0001682852 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Moderna, Inc. reported revenue of $1.94B, down 39.9% from the prior year. The company ran a net loss, with a net margin of -145.2%. It held $12.34B in total assets against $3.69B in total liabilities.

Key ratios (FY2025)

-158.1%
Operating margin
-145.2%
Net margin
-32.6%
Return on equity
-39.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$1.94B$3.24B$6.85B$19.26B$18.47B$60.21M
Cost of Revenue$868.00M$1.46B$4.69B$5.42B$2.62B$8.00M$0$0
Operating Income-$3.07B-$3.94B-$4.24B$9.42B$13.30B-$763.00M-$546.00M-$413.27M-$269.36M-$223.77M
Net Income-$2.82B-$3.56B-$4.71B$8.36B$12.20B-$747.00M-$514.00M-$384.73M-$255.92M-$216.21M
EPS (Diluted)$-7.26$-9.28$-12.33$20.12$28.29$-1.96$-1.55
Total Assets$12.34B$14.14B$18.43B$25.86B$24.67B$7.34B$1.59B$1.96B$1.08B
Total Liabilities$3.69B$3.24B$4.57B$6.74B$10.52B$4.78B$414.61M$431.91M$459.19M
Shareholders' Equity$8.65B$10.90B$13.85B$19.12B$14.14B$2.56B$1.18B$1.53B-$551.37M-$334.81M
Cash & Equivalents$2.60B$1.93B$2.91B$3.21B$6.85B$2.62B$236.00M$658.36M$134.86M$50.08M
Operating Cash Flow-$1.87B-$3.00B-$3.12B$4.98B$13.62B$2.03B-$459.00M-$330.87M-$331.48M$66.73M
Capital Expenditures$192.00M$1.05B$707.00M$400.00M$284.00M$68.00M$32.00M$105.77M$58.40M$33.14M
Shares Outstanding394.00M386.00M382.00M385.00M403.00M399.00M336.54M328.80M65.21M